- Home
- IMSR vs ORIC Comparison
IMSR vs ORIC Comparison
Compare IMSR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | ORIC |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | 74 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 810.9M | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMSR | ORIC |
|---|---|---|
| Price | $7.50 | $7.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | ★ 3.5M | 1.5M |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.33 | $7.23 |
| 52 Week High | $16.38 | $14.93 |
Technical Indicators
Market Signals| Indicator | IMSR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 37.14 |
| Support Level | $5.97 | N/A |
| Resistance Level | $8.80 | $13.89 |
| Average True Range (ATR) | 0.88 | 0.51 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 33.74 | 18.46 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.